Anti-biotin antibody (Anti-biotin Ab)

Anti-biotin and anti-biotin-RBC immune recognition refers to the immunological detection and subsequent clearance of biotinylated substances by pre-existing antibodies in the host. These antibodies, primarily IgG and IgM, are naturally occurring in a significant portion of the human population, likely arising from exposure to biotin-producing gut flora or dietary sources (Mock et al., 1999). When biotinylated red blood cells (biotin-RBCs) or biotin-tagged therapeutics are administered, these antibodies bind to the biotin moiety, acting as opsonins that facilitate phagocytosis by the mononuclear phagocyte system (He et al., 2016). This immune recognition can lead to the rapid removal of biotinylated agents from the circulation, significantly shortening their intended half-life and reducing therapeutic or diagnostic efficacy. Furthermore, the presence of these antibodies can cause significant interference in clinical laboratory immunoassays that utilize the streptavidin-biotin interaction, potentially leading to misdiagnosis (Trambas et al., 2018). Understanding the mechanisms of this recognition is essential for the design of biotin-based delivery systems that can evade immune detection. Strategies to mitigate this include the use of chemically modified biotin or the development of alternative conjugation chemistries that do not trigger an immune response.

Other names

Anti-biotin IgGAnti-biotin IgMBiotin-binding antibodiesAnti-biotin-RBC antibodies

Binding of pre-existing anti-biotin antibodies to biotinylated substrates, leading to accelerated systemic clearance via the mononuclear phagocyte system.